isavuconazole
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Aspergillosis
Conditions
Aspergillosis, Invasive Fungal Infections
Trial Timeline
Apr 22, 2008 → May 5, 2016
NCT ID
NCT00634049About isavuconazole
isavuconazole is a phase 3 stage product being developed by Astellas Pharma for Aspergillosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00634049. Target conditions include Aspergillosis, Invasive Fungal Infections.
What happened to similar drugs?
8 of 15 similar drugs in Aspergillosis were approved
Approved (8) Terminated (6) Active (5)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03149055 | Phase 2 | Completed |
| NCT01657890 | Phase 1 | Completed |
| NCT01555866 | Phase 1 | Completed |
| NCT00634049 | Phase 3 | Completed |
Competing Products
20 competing products in Aspergillosis